1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.__)* Sangamo Biosciences, Inc. ------------------------------ (Name of Issuer) Common Stock ------------------------------ (Title of Class of Securities) 800677106 -------------- (CUSIP Number) May 22, 2000 ------------------------------------------------------ (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
2 SCHEDULE 13G CUSIP No. 800677106 13G Page 2 of 7 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). Stephens Group, Inc. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Arkansas - -------------------------------------------------------------------------------- 5 SOLE VOTING POWER NUMBER OF 2,000,000 SHARES ------------------------------------------------- 6 SHARED VOTING POWER BENEFICIALLY -0- OWNED BY ------------------------------------------------ 7 SOLE DISPOSITIVE POWER EACH 2,000,000 REPORTING ------------------------------------------------ 8 SHARED DISPOSITIVE POWER PERSON -0- WITH - ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,000,000 - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.6% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (See Instructions) HC - --------------------------------------------------------------------------------
3 SCHEDULE 13G CUSIP No. 800677106 13G Page 3 of 7 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). Stephens-Sangamo Biosciences, LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Arkansas - -------------------------------------------------------------------------------- 5 SOLE VOTING POWER NUMBER OF 2,000,000 SHARES ------------------------------------------------- 6 SHARED VOTING POWER BENEFICIALLY -0- OWNED BY ------------------------------------------------ 7 SOLE DISPOSITIVE POWER EACH 2,000,000 REPORTING ------------------------------------------------ 8 SHARED DISPOSITIVE POWER PERSON -0- WITH - ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,000,000 - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.6% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (See Instructions) OO - --------------------------------------------------------------------------------
4 ITEM 1. (a) Name of Issuer: Sangamo Biosciences, Inc. (b) Address of Issuer's Principal Executive Offices: 501 Canal Boulevard, Suite A100 Richmond, CA 94804 ITEM 2. (a) Name of Person Filing Stephens Group, Inc. Stephens-Sangamo Biosciences, LLC (b) Address of Principal Business Office or, if none, Residence 111 Center Street Little Rock, AR 72201 (c) Citizenship Arkansas (d) Title of Class of Securities Common Stock (e) CUSIP Number 800677106 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO Sections 240.13d-1(b), OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: NA (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o) (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c) (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c) (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a - 8) (e) [ ] An investment adviser in accordance with Section 240.13d-1(b)(l)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d 1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(l)(ii)(G);
5 (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Section 240.13d-1(b)(l)(ii)(J). ITEM 4. OWNERSHIP. PROVIDE THE FOLLOWING INFORMATION REGARDING THE AGGREGATE NUMBER AND PERCENTAGE OF THE CLASS OF SECURITIES OF THE ISSUER IDENTIFIED IN ITEM 1. (a) Amount beneficially owned: 2,000,000 (b) Percent of class: 9.6% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 2,000,000 (ii) Shared power to vote or to direct the vote: -0- (iii) Sole power to dispose or to direct the disposition of: 2,000,000 (iv) Shared power to dispose or to direct the disposition of: -0- ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. [ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. NA ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Stephens-Sangamo Biosciences, LLC is an investment LLC of which Stephens Group, Inc. is the manager. Stephens Group, Inc. and the following individuals and entities are members of the LLC: Warren A. Stephens Trust UID 9/30/87 Harriet Calhoun Stephens Trust UID 3/22/84 Warren A. Stephens Grantor Trust UID 9/30/87 Grandchild's Trust #2 Bess C. Stephens Family Trust UID 1/4/85 W. R. Stephens, Jr. Revocable Trust UID 2/19/93 W. R. Stephens, Jr. Children's Trust UID 3/1/95 MAM Holdings, International, Inc.
6 Pamela Diane Stephens Trust One UID 4/10/92 Stephens Investment Partners III LLC Jacoby Enterprises, Inc. J and J Partners Curtis F. Bradbury Douglas H. Martin Douglas H. Martin IRA Martin Family Partnership III C. Ray Gash IRA Robert L. Schulte K. Rick Turner K. Rick Turner IRA Robert Janes Jackson Farrow Jr. IRA William S. Walker Gordon & Amanda Grender, jtwros Andrew Stafford-Deitsch Steve Goldman Frank Lorge Berry Summerour Jason Zhang ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. NA ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NA ITEM 9. NOTICE OF DISSOLUTION OF GROUP NA ITEM 10. CERTIFICATION. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
7 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. May 22, 2000 ----------------------------------------- Date /s/ DAVID A. KNIGHT ----------------------------------------- Signature Executive Vice President, General Counsel ----------------------------------------- Name/Title